Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.55 Average PT from Analysts

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have been given an average rating of "Buy" by the five brokerages that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $3.55.

Several analysts have recently weighed in on LUCD shares. BTIG Research set a $2.00 price objective on shares of Lucid Diagnostics in a report on Tuesday, March 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating and set a $2.00 target price on shares of Lucid Diagnostics in a research note on Thursday, May 15th. Finally, Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the stock a "buy" rating in a report on Friday, June 6th.

Lucid Diagnostics Stock Down 2.3%

NASDAQ:LUCD traded down $0.03 during trading hours on Monday, reaching $1.26. The company had a trading volume of 751,212 shares, compared to its average volume of 586,740. The stock has a 50-day moving average of $1.30 and a two-hundred day moving average of $1.18. Lucid Diagnostics has a one year low of $0.68 and a one year high of $1.80. The firm has a market capitalization of $136.32 million, a PE ratio of -1.11 and a beta of 1.31.

Institutional Trading of Lucid Diagnostics

Hedge funds have recently made changes to their positions in the business. Berkshire Asset Management LLC PA acquired a new stake in Lucid Diagnostics during the 1st quarter valued at $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Lucid Diagnostics during the 1st quarter worth about $37,000. Cubist Systematic Strategies LLC bought a new stake in shares of Lucid Diagnostics during the 1st quarter worth about $39,000. LPL Financial LLC boosted its holdings in shares of Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after buying an additional 12,035 shares during the period. Finally, Sunbelt Securities Inc. acquired a new position in Lucid Diagnostics in the 4th quarter valued at about $67,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.